314P - Bevacizumab in ovarian cancer: Experience in a tertiary hospital of northern Taiwan

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer Agents
Ovarian Cancer
Presenter Wei-Chun Chen
Citation Annals of Oncology (2016) 27 (suppl_9): ix94-ix103. 10.1093/annonc/mdw585
Authors W. Chen, J. Qiu, T. Chang, C. Lai
  • Gynecologic Oncology, Chang Gung Memorial Hospital-Linkou, 333 - Taoyuan/TW



Bevacizumab (BEV) has been used for ovarian cancer (OC) for years in Taiwan, but the associated data and outcome is scanty and less. This retrospective study tracked back the patients with OC treated with BEV and analyzed the report.


All 89 patients with OC had ever treated with BEV during 2009 to 2015 in Chang Gung Memorial Hospital of Linkou branch in Northern Taiwan. According to the means of administration, all the patient can be classified as 6 groups as followings: A-BEV plus chemotherapy (C/T) in initial platinum-resistant (PR) recurrent OC, B-BEV plus C/T in initial platinum-sensitive (PS) recurrent OC, C-BEV alone in recurrent OC, D-BEV plus 1st adjuvant C/T, and E-BEV plus neoadjuvent C/T, F-Intraperitoneal (IP) BEV. Progression-free survival (PFS), overall survival (OS), hazard ratio (HR), overall response rate (ORR), and median BEV cycles were analyzed for group A to E. Clinical improvement of ascites was assessed for group F.


Between early use (only one line of prior C/T) and late use (multiple lines of prior C/T) in patients of group A and B, better PFS (8.27 VS. 3.67, p .037) was found in early use group. No significant differences were found between group A and B (PFS: 4.24 VS. 4.17 months, p .690; OS: 10.06 VS. 9.93 months, p .819; median BEV cycles: 4.63 VS. 5.0 p .992; ORR: 48.1% VS. 53.5%, p .425). Between response and non-response subgroup in patients of group A and B, better outcome is related with endometrioid type cell (HR = 0.28, p .008), well ECOG performance status (HR = 0.51, p .005), and patients without ascites (HR = 0.67, p .004). Between group C with A plus B, BEV alone group has poorer PFS (1.02 VS. 4.19, p .04) and OS (1.42 VS. 9.99 p .001) than BEV plus C/T. In group F, good clinical benefit rate (85.6%) of ascites improvement was noted. Two cases had grade 5 gastrointestinal bleeding and venous/arterial thromboembolic events respectively after BEV used. Grade 3 neutropenia and thrombocytopenia were much more in our study.


Early use of BEV to combine with chemotherapy had significant benefit of PFS in recurrent OC patients. BEV plus chemotherapy is better than BEV alone for recurrent OC. Besides, IP used BEV also has help for clinical ascites.

Clinical trial indentification


Legal entity responsible for the study

Chang Gung Memorial Hospital GYN Oncology Department




All authors have declared no conflicts of interest.